COVID-19 disease. COVID-19
Conditions
Interventions
Intervention 1: Intervention group: 100 outpatients with Covid 19 with respiratory symptoms who in addition to their standard treatment will receive 8mg Dexamethasone (If patient's condition does not
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Outpatients with Covid 19 confirmed by positive PCR test for SARS-CoV-2 or confirmed by abnormal CT scan finding (bilateral, sub pleural, peripheral ground glass opacities), With blood oxygen saturation between 90-95% Patients with severe respiratory symptoms such as cough, shortness of breath and severe shortness of breath or CRP above 20 or after three days of standard treatment worsened symptoms of the disease, including exacerbated fevers, aggravated weakness or aggravated shortness of breath based on the physician's clinical judgment
Exclusion criteria
Exclusion criteria: Patients with a history of underlying disease such as diabetes, malignancies, renal and heart failure, uncontrolled hypertension, and taking immunosuppressive drugs and corticosteroids Patients with other active infections Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| O2 saturation. Timepoint: Before, one and two weeks after dexamethasone treatment. Method of measurement: Pulse Oximeter.;Mortality rate. Timepoint: Before and after dexamethasone treatment. Method of measurement: Observation.;Need for an oxygen therapy. Timepoint: Before and after dexamethasone treatment. Method of measurement: Clinical.;Constitutional. Timepoint: Before, one and two weeks after dexamethasone treatment. Method of measurement: Clinical.;Needs of hospitalization. Timepoint: Before and after treatment. Method of measurement: Observation. | — |
Secondary
| Measure | Time frame |
|---|---|
| CRP laboratory test. Timepoint: Before, one and two weeks after dexamethasone treatment. Method of measurement: Para-clinical.;CBC laboratory test. Timepoint: Before, one and two weeks after dexamethasone treatment. Method of measurement: Para-clinical. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohamadreza Salehi
Tehran University of Medical Sciences
Outcome results
None listed